Epstein Secrets

vents will be the design and initiation of the phase 2b trial in wAMD and possibly the announcement of the results in the upcoming negotiation with Regeneron regarding wAMD project. -Avalanche is well financed with more than a quarter of billion in cash and has some early other projects with REGN. I bel

for maintaining their stable VA while the AVA-101 treated arm was able to maintain (and even improve ) the baseline levels of visual acuity. -More AVA-101 treated subjects improved or maintained stable vision (>-5 letters) with a low number (≤2) of rescue treatments. Specifically, 23.8 percent (treated

does show, in my opinion, is that the "rescue treatment" administrated to the placebo arm was sub-optimal for maintaining their stable VA while the AVA-101 treated arm was able to maintain (and even improve ) the baseline levels of visual acuity. -More AVA-101 treated subjects improved or maintained st

ausing genetic code with only one injection. The treatments generate more than $1.7 billion in annual sales for each company, or about two-thirds of Regeneron's sales. Current options "create a burden and an inability to comply with treatments, which leads to vision loss," Thomas Chalberg, chief executive

ns from another drug. After the company released trial data Monday, shares fell as much as 32 percent to $26.40 in late trading. The study assessed AVA-101's safety for patients with the disease, called wet age-related macular degeneration or wet AMD. Although the study wasn't designed to show statistic

ausing genetic code with only one injection. The treatments generate more than $1.7 billion in annual sales for each company, or about two-thirds of Regeneron's sales. Current options "create a burden and an inability to comply with treatments, which leads to vision loss," Thomas Chalberg, chief executive

ns from another drug. After the company released trial data Monday, shares fell as much as 32 percent to $26.40 in late trading. The study assessed AVA-101's safety for patients with the disease, called wet age-related macular degeneration or wet AMD. Although the study wasn't designed to show statistic